首页
>
期刊首页
>
基因与疾病(英文)
>
2026年1期
>
Transcriptomic landscapes underlying response and resistance to HDAC inhibitor chidamide in triple-negative breast cancer
Transcriptomic landscapes underlying response and resistance to HDAC inhibitor chidamide in triple-negative breast cancer
摘要
Triple-negative breast cancer(TNBC)remains a medical challenge due to limited therapeutics.1 Histone deacety-lases(HDACs)play vital roles in chromatin remodeling and epigenetics,and their dysregulation is implicated in ma-lignancies,including TNBC.2 HDAC inhibitors(HDACis)have shown potent anti-TNBC activity in preclinical studies.3 Unfortunately,their clinical applications are beset by drug resistance,about which little is known.4 This study sys-tematically explored the clinical significance of HDACs and transcriptomic landscapes underlying response and resis-tance to HDAC1/2/3/10 selective inhibitor chidamide,5 the first approved HDACi for solid tumor treatment,in TNBC.
年,卷(期):
2026, 13(1)
机标分类号:
G2
R737.9
R33
在线出版日期:
2026年4月21日